Department of Neurosurgery (M.W., W.A., C.C.-D., N.K., K.S., M.V., T.P.S., H.C., G.A.S.), RWTH Aachen University, Germany.
Department of Neurosurgery, Kantonsspital Aarau, Switzerland (M.W., G.A.S.).
Stroke. 2022 Aug;53(8):2607-2616. doi: 10.1161/STROKEAHA.121.038216. Epub 2022 Jun 8.
Rescue treatment for delayed cerebral ischemia (DCI) after subarachnoid hemorrhage can include induced hypertension (iHTN) and, in refractory cases, endovascular approaches, of which selective, continuous intraarterial nimodipine (IAN) is one variant. The combination of iHTN and IAN can dramatically increase vasopressor demand. In case of unsustainable doses, iHTN is often prioritized over IAN. However, evidence in this regard is largely lacking. We investigated the effects of a classical (iHTN+IAN) and modified (IAN) treatment protocol for refractory DCI in an observational study.
Rescue treatment for DCI was initiated with iHTN (target >180 mm Hg systolic) and escalated to IAN in refractory cases. Until July 2018, both iHTN and IAN were offered in cases refractory to iHTN alone. After protocol modification, iHTN target was preemptively lowered to >120 mm Hg when IAN was initiated (IAN). Primary outcome was noradrenaline demand. Secondary outcomes included noradrenaline-associated complications, brain tissue oxygenation, DCI-related infarction and favorable 6-month outcome (Glasgow Outcome Scale 4-5).
N=29 and n=20 patients were treated according to the classical and modified protocol, respectively. Protocol modification resulted in a significant reduction of noradrenaline demand (iHTN+IAN 0.70±0.54 µg/kg per minute and IAN 0.26±0.20 µg/kg per minute, <0.0001) and minor complications (15.0% versus 48.3%, unadjusted odds ratio, 0.19 [95% CI, 0.05-0.79]; <0.05) with comparable rates of major complications (20.0% versus 20.7%, odds ratio, 0.96 [0.23-3.95]; =0.95). Incidence of DCI-related infarction (45.0% versus 41.1%, odds ratio, 1.16 [0.37-3.66]; =0.80) and favorable clinical outcome (55.6% versus 40.0%, odds ratio, 1.88 [0.55-6.39]; =0.32) were similar. Brain tissue oxygenation was significantly higher with IANonly (26.6±12.8, 39.6±15.4 mm Hg; <0.01).
Assuming the potential of iHTN to be exhausted in case of refractory hypoperfusion, additional IAN may serve as a last-resort measure to bridge hypoperfusion in the DCI phase. With close monitoring, preemptive lowering of pressure target after induction of IAN may be a safe alternative to alleviate total noradrenaline load and potentially reduce complication rate.
蛛网膜下腔出血后迟发性脑缺血(DCI)的抢救治疗可包括诱导性高血压(iHTN),在难治性病例中,还可采用血管内方法,其中选择性、持续的动脉内尼莫地平(IAN)是一种变体。iHTN 和 IAN 的联合应用可显著增加血管加压剂的需求。在不可持续剂量的情况下,iHTN 通常优先于 IAN。然而,这方面的证据在很大程度上是缺乏的。我们在一项观察性研究中调查了经典(iHTN+IAN)和改良(IAN)治疗难治性 DCI 方案的效果。
采用 iHTN(目标收缩压>180mmHg)对 DCI 进行抢救治疗,并在难治性病例中逐步升级为 IAN。直到 2018 年 7 月,当 iHTN 单独治疗无效时,两种方法都可以选择。在方案修改后,当开始 IAN 时,iHTN 的目标值被预先降低到>120mmHg(IAN)。主要结局是去甲肾上腺素的需求。次要结局包括去甲肾上腺素相关并发症、脑氧合、DCI 相关梗死和 6 个月的良好预后(格拉斯哥预后量表 4-5)。
分别按照经典和改良方案治疗 29 例和 20 例患者。方案修改后,去甲肾上腺素的需求显著减少(iHTN+IAN 为 0.70±0.54μg/kg/分钟,IAN 为 0.26±0.20μg/kg/分钟,<0.0001),并发症发生率降低(15.0%与 48.3%,调整后优势比,0.19[95%可信区间,0.05-0.79];<0.05),但主要并发症发生率相似(20.0%与 20.7%,优势比,0.96[0.23-3.95];=0.95)。DCI 相关梗死的发生率(45.0%与 41.1%,优势比,1.16[0.37-3.66];=0.80)和良好的临床预后(55.6%与 40.0%,优势比,1.88[0.55-6.39];=0.32)相似。仅 IAN 治疗时脑氧合显著升高(26.6±12.8,39.6±15.4mmHg;<0.01)。
假设在难治性灌注不足的情况下 iHTN 的潜力已经耗尽,额外的 IAN 可能是 DCI 阶段缓解灌注不足的最后手段。在密切监测下,IAN 诱导后预先降低压力目标可能是一种安全的替代方法,可以减轻总的去甲肾上腺素负荷,并可能降低并发症发生率。